Mount Sinai Health System has appointed Livia Agnes Veress, MD, as Vice Chair for Research in the Department of Pediatrics and System Chief of Pediatric Pulmonology, effective Tuesday, September 1. She will also serve as a Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and an attending physician at Mount Sinai Kravis Children’s Hospital.

A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.

Researchers at Liverpool School of Tropical Medicine have concluded that rapid diagnosis is within reach for the ‘missed millions’ of people living with TB.

Theranostics is now a mature cancer treatment modality, and The Journal of Nuclear Medicine (JNM) is capturing the moment in a new supplement: “Theranostics: The State of the Art.” Guest edited by Ken Herrmann, MD, MBA, with JNM Editor-in-Chief Johannes Czernin, MD, the supplement brings together top voices in the field to map out where theranostics stands today and where it’s headed next.

Genetic information may play an increasingly important role in the personalized preventive medicine of the future. Whole-genome sequencing could open up new possibilities for identifying susceptibility and risk for specific diseases even before symptoms appear, emphasizes Dr. Gyula Richárd Nagy, a clinical geneticist at Semmelweis University. However, to achieve this, we must first accurately ‘read’ our genome — that is, the billions of DNA letters — with increasing precision. We must also ensure that the reference base we are comparing it to is appropriate. A study published in the prestigious US journal GeroScience, which involved researchers from Semmelweis University, sheds light on this important yet little-known issue for the future of preventive genomics.

Early detection could help patients start Alzheimer's treatments when they deliver the greatest value to patients, families and society. 

A gene involved in cell signaling and lipid metabolism, CTDNEP1, is associated with poorer survival in clear cell renal cell carcinoma (ccRCC), a study from Tokyo University of Science and Nippon Medical School has found. Researchers analyzed publicly available cancer databases to examine CTDNEP1 expression in ccRCC and papillary RCC. They found that higher CTDNEP1 expression was associated with poorer survival in ccRCC, suggesting its potential as a candidate prognostic biomarker for this subtype.